What are the treatments for Primary Myelofibrosis ?
Treatment of primary myelofibrosis in patients without signs or symptoms is usually watchful waiting.    Patients with primary myelofibrosis may have signs or symptoms of anemia. Anemia is usually treated with transfusion of red blood cells to relieve symptoms and improve quality of life. In addition, anemia may be treated with:             -  Erythropoietic growth factors.     -  Prednisone.     -  Danazol.     -  Thalidomide, lenalidomide, or pomalidomide, with or without prednisone.            Treatment of primary myelofibrosis in patients with other signs or symptoms may include the following:            -  Targeted therapy with ruxolitinib.     -  Chemotherapy.     -  Donor stem cell transplant.     - Thalidomide, lenalidomide, or pomalidomide.     -  Splenectomy.     -  Radiation therapy to the spleen, lymph nodes, or other areas outside the bone marrow where blood cells are forming.     -  Biologic therapy using interferon alfa or erythropoietic growth factors.     - A clinical trial of other targeted therapy drugs.            Check the list of NCI-supported cancer clinical trials that are now accepting patients with primary myelofibrosis. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your doctor about clinical trials that may be right for you. General information about clinical trials is available from the NCI website.